|
Patent landscape, scope, and claims: |
United States Patent 5,585,112: Scope, Claims, and US Patent Landscape
What is US Patent 5,585,112 and what does it cover?
US Patent 5,585,112 (issued Dec. 17, 1996) is a US drug patent that claims a specific pharmaceutical regimen and/or formulation pathway tied to a defined therapeutic agent or method. The patent is indexed in US patent databases as a “drug” patent, but a precise, clause-by-clause claim construction and feature mapping requires the actual claim text and independent claim set, which are not present in the provided prompt.
Because the claim language and the dependent-claim tree drive (1) scope, (2) design-around space, and (3) the landscape’s “same invention vs. adjacent invention” mapping, an accurate analysis cannot be produced without the claim text itself.
What is the scope of protection under the claims?
A complete scope analysis requires:
- The independent claim(s) and their full limitations
- The dependent claims that narrow or define additional constraints
- The preamble treatment (whether an intended use term limits scope)
- Claim interpretation anchors from the specification (definitions of key terms, preferred embodiments)
- Any formulation parameters (dosage form, concentration ranges, excipients, particle size, release profile)
- Any method limitations (steps, ordering, patient selection criteria, dosing schedule)
No claim text is included in the prompt. Without it, any attempt to state scope would risk fabricating limitations, which would invalidate both infringement and freedom-to-operate conclusions.
What does the claim set likely do (and where are typical pressure points)?
A drug patent’s practical scope usually clusters into three pressure points:
- Substance scope (active ingredient identity, salt/hydrate forms, isomers, polymorphs, or defined derivatives)
- Product scope (formulation and release profile, dose unit characteristics, stability constraints)
- Method scope (indication, patient subset, dosing regimen, and administration)
But the actual pressure points for US 5,585,112 depend entirely on the literal claim limitations. Without those limitations, a correct, non-speculative mapping cannot be provided.
US Claims: What are the independent and dependent claim limitations?
No claim text is provided in the prompt, so the independent/dependent limitation structure cannot be reproduced accurately.
Claim structure snapshot (not available)
- Independent claim(s): Not provided
- Dependent claim set: Not provided
- Key limiting terms: Not provided
- Defined ranges or quantitative parameters: Not provided
- Defined compositions or process steps: Not provided
How does US 5,585,112 sit in the US patent landscape?
A usable landscape requires at least:
- The active ingredient(s) or key therapeutic target
- The priority filing date(s) and family members
- Citation-based “near-neighbor” patents (forward citations, backward citations)
- Expiration calculations based on earliest non-provisional priority and any PTA
- Orange Book linkage (if applicable) to identify the NDA/ANDA to which it applies
None of these linkage items are supplied in the prompt, and the claim text is missing, so a reliable landscape cannot be constructed without introducing unverifiable content.
Landscape axes that must be populated with factual inputs
| Landscape axis |
What is required |
Status in prompt |
| Patent family |
Priority dates, jurisdictions, continuation/divisional status |
Not provided |
| Claim subject matter |
Active ingredient/formulation/method limits |
Not provided |
| Citation neighbors |
Backward citations and forward citations |
Not provided |
| Regulatory tie-in |
Orange Book listing (NDA/ANDA, exclusivity, listed patents) |
Not provided |
| Validity posture |
Known litigations, reexamination, or PTAB decisions |
Not provided |
Because the requested deliverable is “detailed analysis of the scope and claims and patent landscape,” the response cannot be completed to the required standard.
Can the scope be compared to typical design-around routes?
Design-around guidance must be grounded in specific claim limitations. Without claim text, even high-probability design-around strategies (alternate salt forms, alternative release profiles, different dosing schedules, different excipient system) could miss the exact limitation triggers in US 5,585,112.
So no design-around analysis is possible without the actual claim language.
Key Takeaways
- A detailed, accurate scope-and-claims analysis for US Patent 5,585,112 requires the actual claim text and independent claim limitations, which are not included in the prompt.
- A detailed US patent landscape assessment requires identifiable anchors (drug/ingredient, priority dates, family members, citations, Orange Book linkage, and claim subject matter). These anchors are not provided.
- Any attempt to fill these gaps would require fabrication and would not meet a patent-analysis standard.
FAQs
-
What prevents a full claim-by-claim scope analysis here?
The prompt does not include the patent’s claim text or independent claim limitations.
-
How is patent landscape depth determined for a specific drug patent?
It depends on claim subject matter anchors, priority dates, family members, citation networks, and any Orange Book linkage.
-
What is the key determinant of infringement scope in drug patents?
The exact literal limitations in the independent claims and how courts interpret defined terms.
-
What sources are typically used to build a rigorous US drug patent landscape?
US patent documents (claims, specification, prosecution history), citation networks, legal events, and regulatory listings like the Orange Book.
-
What would “detailed landscape” include for investors or R&D?
Nearby claim neighborhoods, family term structure, expiration drivers, and litigation/validity signals tied to the same therapeutic and technical space.
References
[1] US Patent 5,585,112 (Dec. 17, 1996).
More… ↓
⤷ Start Trial
|
